Glofitamab, a drug for diffuse large B-cell lymphoma to be made available on the NHS
United Kingdom
Hundreds of people with the blood cancer, known as diffuse large B-cell lymphoma (DLBCL) are set to benefit from a new treatment – glofitamab – on the NHS.
DLBCL is a type of non-Hodgkin lymphoma. The drug, which has the brand name Columvi® will be made available within weeks for those with DLBCL who have had two or more cancer treatments and have relapsed
A new, readily available treatment will give people with blood cancer hope that they’ll be able to spend more time doing the things they love.
- Sarah McDonald, Deputy Director of Research at Blood Cancer UK
NHS England will use the Cancer Drugs Fund (CDF) to provide fast-tracked access to the treatment.
The drug is administered as a four hour diffusion.
Sarah McDonald, Deputy Director of Research at Blood Cancer UK said:
“At Blood Cancer UK we hear from people living with diffuse large B-cell lymphoma (DLBCL), whose cancer has returned or progressed further. It can be an emotional rollercoaster for many, with some people struggling with the symptoms of the disease, the side effects of treatments the uncertainty of what the future might bring.
“Research and innovation in this area is vital, and a treatment for people with this blood cancer that affects around 5,500 people, and has returned can improve both quality and length of life is hugely important. A new, readily available treatment will give people with blood cancer hope that they’ll be able to spend more time doing the things they love.”